Analysis of Suffix Use for Biosimilar Product Identification in Postmarketing Adverse Event Reporting Authors: Danijela Stojanovic, Lisa Wolf, M. Stacey Ricci, Monica A. Muñoz Published: 2026 ABSTRACT Accurate identification of medicines used in adverse event reports is crucial for effective postmarketing safety surveillance. The US Food and Drug Administration's (FDA) four‐letter suffix naming convention was designed to facilitate accurate biological product identification, but the extent to which these suffixes have been incorporated into biosimilar reporting remains unclear. We conducted a cross‐sectional analysis of US adverse event reports for all 72 FDA‐approved biosimilar products in the FDA Adverse Event Monitoring System (AEMS) received through August 31, 2025, evaluating the proportion of reports containing a four‐letter suffix, proprietary name, or other manufacturer identifiers. Of 24,711 reports analyzed, 12.7% (n = 3126) contained a biosimilar suffix, whereas 98.2% (n = 24,264) contained a proprietary name and 82% reported the manufacturer name. Suffixes served as the sole product identifier in only 1.7% (n = 413). These suffix‐only reports were distinct: more frequently submitted directly to FDA (86.2% vs. 15.0%), by healthcare professionals (73.3% vs. 59.0%), commonly originated from Veterans Affairs Medical Centers and specialty pharmacies and involved more serious outcomes (47.7% vs. 27.9%), suggesting certain organizational preferences favoring nonproprietary name reporting. The product distribution also differed, with adalimumab‐aacf most common in suffix‐only reports (18.9%) vs. infliximab‐dyyb overall (21.1%). Manufacturer information was present in 42.6% of suffix‐only reports. These results suggest FDA's nonproprietary naming convention has achieved limited implementation for biosimilars in AEMS reporting practices, and other information present in AEMS reports may be sufficient for accurately identifying biosimilar products. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? The FDA established a nonproprietary naming convention in 2017 requiring certain biological products to have a core name paired with a unique four‐letter suffix to facilitate pharmacovigilance, enable accurate product identification, and minimize inadvertent substitution. However, the real‐world utility of this naming convention in pharmacovigilance was unclear. WHAT QUESTION DID THIS STUDY ADDRESS? This study examined the extent to which FDA‐designated four‐letter biosimilar suffixes are utilized in adverse event reporting within the FDA Adverse Event Monitoring System (AEMS) and evaluated their contribution to accurate product identification compared to other identifiers. WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? Analysis of 24,711 US biosimilar adverse event reports through August 2025 revealed that FDA‐designated suffixes appeared in only 12.7% of reports, whereas proprietary names remained nearly universal at 98.2%. Suffixes functioned as the sole product identifier in fewer than 2% of reports. Manufacturer information was documented in over 80% of reports, and 99% of biosimilar products were identifiable through existing identifiers. Suffix‐only reports were predominantly direct FDA submissions (86.2%), were more commonly submitted by healthcare professionals (73.3%), and documented serious outcomes more frequently. Even for biosimilars with marketed unbranded products, proprietary name use remained dominant. HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? These findings demonstrate that the suffix‐based naming convention has achieved limited practical implementation in pharmacovigilance, with existing identifiers serving as primary drivers of product‐level attribution. This evidence underscores the importance of evaluating regulatory policies on their practical implementation and real‐world impact. These insights may inform future pharmacovigilance approaches that better align with actual reporting practices. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? The FDA established a nonproprietary naming convention in 2017 requiring certain biological products to have a core name paired with a unique four‐letter suffix to facilitate pharmacovigilance, enable accurate product identification, and minimize inadvertent substitution. However, the real‐world utility of this naming convention in pharmacovigilance was unclear. WHAT QUESTION DID THIS STUDY ADDRESS? WHAT QUESTION DID THIS STUDY ADDRESS? WHAT QUESTION DID THIS STUDY ADDRESS? This study examined the extent to which FDA‐designated four‐letter biosimilar suffixes are utilized in adverse event reporting within the FDA Adverse Event Monitoring System (AEMS) and evaluated their contribution to accurate product identification compared to other identifiers. WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? Analysis of 24,711 US biosimilar adverse event reports through August 2025 revealed that FDA‐designated suffixes appeared in only 12.7% of reports, whereas proprietary names remained nearly universal at 98.2%. Suffixes functioned as the sole product identifier in fewer than 2% of reports. Manufacturer information was documented in over 80% of reports, and 99% of biosimilar products were identifiable through existing identifiers. Suffix‐only reports were predominantly direct FDA submissions (86.2%), were more commonly submitted by healthcare professionals (73.3%), and documented serious outcomes more frequently. Even for biosimilars with marketed unbranded products, proprietary name use remained dominant. HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? These findings demonstrate that the suffix‐based naming convention has achieved limited practical implementation in pharmacovigilance, with existing identifiers serving as primary drivers of product‐level attribution. This evidence underscores the importance of evaluating regulatory policies on their practical implementation and real‐world impact. These insights may inform future pharmacovigilance approaches that better align with actual reporting practices. Biosimilar products (biosimilars) represent an important strategy for reducing healthcare costs and improving patient access in the United States, and federal agencies have prioritized efforts to facilitate biosimilar development and adoption. 1 , 2 , 3 , 4 The approval of the first biosimilar product in the United States, filgrastim‐sndz (Zarxio), in 2015 marked a pivotal milestone in the evolution of biologic drug development and regulation. That same year, the Food and Drug Administration (FDA) issued draft guidance with recommendations on how companies should name their biological products and issued final guidance, “Nonproprietary Naming of Biological Products,” in January 2017. 5 This guidance established a distinctive nonproprietary naming convention for biologic products where the nonproprietary name for each originator biological product, related biological product, and biosimilar product consists of a core name paired with a unique, four‐letter suffix, devoid of meaning. The guidance outlined three primary purposes for this naming convention: facilitating pharmacovigilance, enabling accurate product identification by healthcare practitioners and patients, and minimizing inadvertent substitution. At the time of the guidance publication, there was concern that traditional identifiers, such as proprietary names, manufacturer information, and national drug codes (NDCs), were often inconsistently captured in adverse event (AE) reports, billing records, and electronic health data, limiting the ability to distinguish among products sharing the same proper name. By introducing a distinguishing four‐letter suffix to the nonproprietary name of each biological product, the FDA aimed to establish a consistent and enduring identifier that supports precise product‐level attribution of AEs, strengthens postmarketing safety monitoring, and improves the reliability of pharmacovigilance data for both originator and biosimilar products. In passive surveillance systems such as the FDA Adverse Event Monitoring System (AEMS), 6 the success of the suffix convention depends heavily on the accuracy and consistency with which reporters include the full nonproprietary name. Despite its regulatory intent, the suffix‐based approach has generated debate regarding its practical impact. Concerns have been raised about the reliability of suffix incorporation in spontaneous AE reports, given variability in how healthcare professionals, patients, and data systems record product identifiers. 7 , 8 , 9 , 10 , 11 , 12 The naming approach also diverges from other international regulatory authorities, and some stakeholders have expressed concern that appending meaningless letters to nonproprietary names may inadvertently cause confusion or suggest product inferiority, potentially affecting biosimilar uptake. 13 As biosimilar utilization continues to expand, evaluating how effectively the FDA's naming convention supports pharmacovigilance activities has become increasingly important. Although the suffix was designed to facilitate product‐level traceability, the extent to which these suffixes are incorporated into real‐world AE reporting remains unclear. This study examines the role of distinguishable biosimilar suffixes within AEMS and evaluates their contribution to accurate product identification. MATERIALS AND METHODS Study design and data source We conducted a cross‐sectional analysis of US AE reports for biosimilar products in the AEMS received through August 31, 2025. This activity does not meet the regulatory definition of human participant research; therefore, institutional review board approval and informed consent were not required in accordance with the Common Rule (45 Code of Federal Regulations (CFR) §46). AEMS is a unified platform for FDA‐regulated products and includes more than 32 million reports for drugs and biological products dating back to 1968 that were previously maintained in the FDA AE Reporting System. Each report includes a narrative description, suspect products, and reporter information; additional details such as product manufacturer names, NDCs, and event outcomes may also be provided. Approximately 95% of reports are submitted by manufacturers (who are legally required to forward reports they receive), whereas 5% are submitted directly to the FDA by healthcare professionals, consumers, and other sources. These reports utilize standardized Medical Dictionary for Regulatory Activities (MedDRA) terminology and adhere to International Conference on Harmonization standards (ICH E2B). 14 Report identification, classification, and data extraction Reports were identified using the nonproprietary names of all 72 FDA‐approved biosimilars in the “product active ingredient” field in AEMS (e.g., adalimumab‐atto, bevacizumab‐awwb) 15 at the time of the analysis (Table S1 ). For each report, we extracted the following characteristics: report type (direct, 15‐day, 30‐day, periodic), report source (spontaneous, study, literature, other), reporter type (healthcare professional or consumer), reported outcomes (death, hospitalization, life threatening, disability, congenital anomaly, required intervention, other serious), and biosimilar product active ingredient. For reports with multiple versions submitted over time, we analyzed the most recent version. Within these reports, we evaluated the presence of three key product identifiers: (1) the FDA‐designated four‐letter biosimilar suffix, (2) proprietary names, and (3) 351(k) biologics license application (BLA) product codes. These identifiers were assessed across two unstructured text sources within reports: (1) the verbatim suspect product field, which captures the product name as originally reported and (2) the free‐text narrative, which contains the reporter's detailed description of the AE. We used text‐string searches to detect the presence of these identifiers, systematically scanning each report for character strings corresponding to biosimilar proprietary names, four‐letter suffixes, and 351(k) product codes based on our reference list of FDA‐approved biosimilars (Table S1 ). Importantly, the presence of suffixes in structured FAERS fields (product active ingredient or product name) does not necessarily reflect reporter usage, as verbatim products are automatically mapped to standardized dictionary terms. For example, if a reporter provides “Inflectra” as the verbatim suspect product, the report is automatically coded to infliximab‐dyyb in the structured active ingredient field. We categorized each report into one of three groups based on the type of product identification information available: (1) proprietary name/product code reports: reports that included a biosimilar proprietary name or a 351(k) biologics license application (BLA) product code; (2) suffix‐reported: reports that contained a four‐letter biosimilar suffix, either alone or in combination with other product identifiers; and (3) suffix‐only: reports that contained a biosimilar suffix but did not include a proprietary name or 351(k) product code. For suffix‐only reports, we manually examined additional data fields for manufacturer identification information, including the suspect product manufacturer name, verbatim suspect product, NDC numbers, application numbers, and narrative text. To assess potential misclassification of reports coded to the reference product ingredient but not to the biosimilar product active ingredient (e.g., reports coded to infliximab and not infliximab‐abda, infliximab‐axxq, infliximab‐dyyb, infliximab‐qbtx), we conducted an additional analysis focusing on five biologics with the highest numbers of US biosimilar reports in AEMS. We searched the narrative text and verbatim suspect product fields of reports coded only to reference product active ingredients for mentions of relevant biosimilar suffixes. Reports containing suffix mentions were then manually reviewed to determine whether they represented true misclassification. Statistical analysis We calculated descriptive statistics for report characteristics overall and stratified by report categorization (all reports, suffix‐reported, and suffix‐only). We identified the most frequently reported biosimilar product active ingredients overall and within each category. All analyses were performed using JMP version 18.0 (SAS Institute Inc.). RESULTS Suffix utilization in biosimilar AE reports Our analysis included 24,711 US reports for biosimilar products submitted to AEMS through August 31, 2025. FDA‐designated suffixes appeared in 12.7% (3126) of reports, proprietary names appeared in 98.2% (24,264), and 351(k) product codes in 0.4% (88) (Table 1 ). When suffixes were included in reports, they most frequently appeared in the narrative field (84.7%, 2649/3126) rather than in the verbatim product field (63.3%, 1979/3126). Among reports containing suffix information, only 13.2% (413/3126) relied exclusively on the suffix without accompanying proprietary names or 351(k) product codes, representing 1.7% of all biosimilar reports. When biosimilars were listed among the first five suspect products (99.6% of all biosimilar reports; 24,622/24,711), a suspect product manufacturer name was documented for the biosimilar in 82% (20,292/24,622) of reports. Table 1Use of proprietary name, 351(k) product code, and suffix information in AEMS biosimilar reportsProduct identifiera Reports, no. (%)Information location, no. (%)Sole identifier, no. (%)Verbatim productNarrativeProprietary nameb 24,264 (98.2)24,125 (99.4)22,110 (91.1)21,138 (85.5)Suffix3126 (12.7)1979 (63.3)2649 (84.7)413 (1.7)351(k) Product Code88 (0.4)76 (86.4)75 (85.2)28 (0.1)AEMS, FDA Adverse Event Monitoring System. a More than one identifier could be provided for each report. b Includes 14 reports with misspelled proprietary names. Use of proprietary name, 351(k) product code, and suffix information in AEMS biosimilar reports AEMS, FDA Adverse Event Monitoring System. More than one identifier could be provided for each report. Includes 14 reports with misspelled proprietary names. Manufacturer information in suffix‐only reports For the 413 suffix‐only reports, we manually reviewed additional data fields (as described in Methods) to determine whether the biosimilar manufacturer could be identified. This detailed review revealed that 42.6% (176/413) of suffix‐only reports contained information identifying the specific biosimilar manufacturer (Table 2 ). The suspect product manufacturer field was the primary source of manufacturer identification, present in 98% (173/176) of reports containing manufacturer information. Application numbers uniquely identified the biosimilar manufacturer in two additional reports, whereas NDC information contributed to identification in one additional case. Table 2Availability of manufacturer information in suffix‐only reports a (n = 413)Data fieldReports, no. (%)Any data fieldb 176 (42.6)Suspect product manufacturer173 (41.9)National drug code80 (19.4)Application number64 (15.5)Verbatim product41 (9.9)Narrative4 (1.0) a Reports containing suffix information but lacking proprietary names or product codes. b Each report may include biosimilar manufacturer information in multiple data fields; percentages do not sum to 100%. Availability of manufacturer information in suffix‐only reports a (n = 413) Reports containing suffix information but lacking proprietary names or product codes. Each report may include biosimilar manufacturer information in multiple data fields; percentages do not sum to 100%. Characteristics of suffix‐only reports Suffix‐only reports exhibited distinct characteristics compared to the overall biosimilars reported (Table 3 ). A higher proportion of suffix‐only reports were submitted directly to the FDA through the MedWatch program rather than through manufacturer reporting channels (86.2%, 365/413 vs. 15.0%, 3700/24,711 for all reports). Suffix‐only reports more frequently documented outcomes requiring intervention (21.1%, 87/413 vs. 1.1%, 266/24,711 overall) and hospitalization (19.4%, 80/413 vs. 7.2%, 1777/24,711 overall). Nearly half of suffix‐only reports (47.7%, 197/413) involved any serious outcome, compared to 27.9% (6898/24,711) of all biosimilar reports. Healthcare professionals submitted 73.3% (303/413) of suffix‐only reports, a higher proportion than observed in the overall dataset (59.0%, 14,588/24,711). Table 3Characteristics of biosimilar reports in AEMS by suffix reporting status through August 31, 2025 (N = 24,711)CharacteristicAll reports (N = 24,711), No. (%)Suffix‐reporteda (n = 3126), No. (%)Suffix‐onlyb (n = 413), No. (%)Report typeDirect3700 (15.0)608 (19.5)356 (86.2)15‐Day4729 (19.1)735 (23.5)24 (5.8)30‐Day1053 (4.3)118 (3.8)—Periodic15,229 (61.2)1665 (53.3)33 (8.0)Report sourceSpontaneous report23,107 (93.5)2861 (91.5)397 (96.1)Report from study1397 (5.6)136 (4.4)—Literature171 (0.7)125 (4.0)16 (3.9)Other36 (0.2)4 (0.1)—Reported outcomeCongenital anomaly6 (<0.1)6 (0.2)0.0Death1712 (7.1)149 (4.8)4 (1.0)Disability112 (0.5)25 (0.8)4 (1.0)Hospitalization1777 (7.2)269 (8.6)80 (19.4)Life threatening172 (0.7)44 (1.4)14 (3.4)Other serious3693 (15.4)397 (12.7)58 (14)Required intervention266 (1.1)135 (4.3)87 (21.1)Any serious outcome6898 (27.9)812 (26)197 (47.7)Reporter health professional14,588 (59.0)1496 (47.9)303 (73.3)AEMS, FDA Adverse Event Monitoring System. a Reports containing suffix information with or without other identifiers. b Reports containing suffix information but lacking proprietary names or 351(k) product codes. Characteristics of biosimilar reports in AEMS by suffix reporting status through August 31, 2025 (N = 24,711) AEMS, FDA Adverse Event Monitoring System. Reports containing suffix information with or without other identifiers. Reports containing suffix information but lacking proprietary names or 351(k) product codes. Product‐specific patterns in suffix reporting The distribution of biosimilar products differed between suffix‐only reports and the all reports population (Table 4 ). Among all reports, infliximab‐dyyb accounted for the largest proportion of reports (21.1%, 5212/24,711), followed by bevacizumab‐awwb (14.0%, 3461/24,711), and rituximab‐abbs (7.5%, 1860/24,711). Among suffix‐only reports, adalimumab‐aacf was most frequently reported representing 18.9% (78/413) of such reports, followed by rituximab‐pvvr at 13.8% (57/413), and adalimumab‐adaz at 11.4% (47/413). Insulin glargine‐yfgn, which constituted 38.8% (1212/3126) of all reports containing suffix information, accounted for only 10.7% (44/413) of suffix‐only reports. Table 4Most frequent biosimilar product active ingredients in AEMS received through August 31, 2025, by suffix reporting status (N = 24,711)All reports (N = 24,711), No. (%)Suffix‐reported (n = 3126), No. (%)Suffix‐only (n = 413), No. (%)Infliximab‐dyyb5212 (21.1)Insulin glargine‐yfgn1212 (38.8)Adalimumab‐aacf78 (18.9)Bevacizumab‐awwb3461 (14.0)Pegfilgrastim‐cbqv544 (17.4)Rituximab‐pvvr57 (13.8)Rituximab‐abbs1860 (7.5)Infliximab‐dyyb142 (4.5)Adalimumab‐adaz47 (11.4)Insulin glargine‐yfgn1755 (7.1)Pegfilgrastim‐jmdb112 (3.6)Insulin glargine‐yfgn44 (10.7)Filgrastim‐sndz1695 (6.9)Rituximab‐pvvr98 (3.1)Infliximab‐abda38 (9.2)Adalimumab‐adaz1564 (6.3)Adalimumab‐aacf89 (2.8)Adalimumab‐ryvk29 (7.0)Epoetin alfa‐epbx1204 (4.9)Infliximab‐abda88 (2.8)Infliximab‐dyyb29 (7.0)Trastuzumab‐anns1191 (4.8)Adalimumab‐atto86 (2.8)Adalimumab‐bwwd15 (3.6)Adalimumab‐atto1094 (4.4)Epoetin alfa‐epbx78 (2.5)Rituximab‐abbs11 (2.7)Pegfilgrastim‐cbqv707 (2.9)Adalimumab‐adaz79 (2.4)Adalimumab‐adbm7 (1.7)AEMS, FDA Adverse Event Monitoring System. Most frequent biosimilar product active ingredients in AEMS received through August 31, 2025, by suffix reporting status (N = 24,711) AEMS, FDA Adverse Event Monitoring System. Assessment of potential misclassification Among 25,717 infliximab reference product reports, we identified 25 containing suffix mentions, of which 7 (0.03%) were confirmed as misclassified upon manual review. Similarly, among 25,109 rituximab reference product reports, 12 contained suffix mentions, with 3 (0.01%) confirmed as misclassified. For filgrastim (4619 reference product reports), 19 suffix mentions yielded 3 (0.06%) confirmed misclassifications. Bevacizumab showed 24 suffix mentions among 12,720 reference product reports, with 7 (0.06%) confirmed misclassifications. For insulin, 36 suffix mentions were identified among 33,718 reference product reports, of which 28 (0.08%) were confirmed as misclassified. DISCUSSION The findings from this analysis reveal substantial limitations in the real‐world implementation of the FDA's nonproprietary naming convention for biosimilars within the AEMS database. Despite the regulatory intent to enhance pharmacovigilance through distinguishable four‐letter suffixes, our data demonstrate that these suffixes appear in only 12.7% of biosimilar AE reports, whereas proprietary names remain nearly universal at 98.2%. More critically, suffixes function as the sole product identifier in fewer than 2% of reports, with 99% of biosimilar products currently identifiable through existing mechanisms. Although the FDA's guidance outlined three purposes for the naming convention (facilitating pharmacovigilance, accurate identification by healthcare practitioners and patients, and minimizing inadvertent substitution), this analysis specifically addresses pharmacovigilance by examining suffix utility in AE reporting. We did not evaluate the naming convention's impact on product identification in clinical practice or inadvertent substitution prevention, both of which may require different data sources and methodological approaches. The high presence of proprietary names in AE reporting aligns with the broader approach to product identification in healthcare systems; studies demonstrate preferential use of proprietary names rather than nonproprietary names because they are typically shorter, more memorable, and have less syllabic complexity. 16 , 17 , 18 The nonproprietary names for biologic products, composed of the reference product's core name followed by four‐letter suffixes, are, by design, less memorable than established proprietary names. A survey conducted by the US Department of Veterans Affairs found that respondents commonly used brand names to distinguish biosimilar products because they were easier to remember, consistent with our observed reporting patterns. 9 The distinct profile of suffix‐only reports, which represent a very small proportion of reports, provides important insights into when the suffix‐containing nonproprietary name is used. These suffix‐only reports (1.7%; 413/24,711) were predominantly direct submissions to FDA (86.2% vs. 15% overall), were more commonly submitted by healthcare professionals (73.3% vs. 59.0% overall), and represented distinctly different products than the overall cohort. Although suffix‐only reports were associated with a higher proportion of serious outcomes, we caution against interpreting this as evidence of disproportionate suffix utility in clinically complex cases, as this pattern more likely reflects the characteristics of their submitters. Our post hoc examination of suffix‐only reports found more than half originated from Veterans Affairs Medical Centers and specialty pharmacies, indicating that certain organizations may have implemented practices favoring nonproprietary name reporting. The emergence of unbranded biological products 19 presents a scenario in which suffix‐based identification could be more relevant for passive surveillance. Unbranded biological products are products marketed under a brand name biological product's application but without the proprietary name. If proprietary names are not included on product labeling, distinguishing biosimilar products from one another theoretically creates greater reliance on the suffix for reporting. Recognizing the use of reported manufacturer information for product identification for generic drugs, we evaluated inclusion of manufacturing information in biosimilar reports. Interestingly, in practice, over 80% of biosimilar reports (in which the biosimilar was listed among the first five suspect products) included a suspect product manufacturer name for the biosimilar. Additionally, even for biosimilar products with marketed unbranded versions, proprietary name use was dominant in reports (Table S2 ). Insulin glargine‐yfgn, which had the most reports among biosimilars with marketed unbranded products, showed proprietary name reporting in nearly all cases (97.4%), despite significant unbranded market share. 20 This pattern likely reflects manufacturer reporting practices and preferential use of proprietary names by reporters. Taken together, the data suggest reporting of the manufacturer directly or through the reported proprietary name even if the report likely involved the unbranded product can be an alternative to suffix‐based identification. In passive surveillance systems, product identifiers support pharmacovigilance when they are consistently captured in reports, so low utilization may limit utility. The infrequent reporting of biosimilar suffixes reflects broader data quality challenges beyond the naming convention itself. 21 , 22 Accurate manufacturer attribution is notoriously difficult and not unique to biosimilars. NDCs, which could provide precise product identification, are infrequently reported. Manufacturer names are also frequently missing or unreliable, as some companies may attribute AEs to their own products by default when they cannot identify the actual suspected product manufacturer. 16 , 23 These systemic quality issues persist despite educational efforts and reporting form changes, suggesting a more fruitful solution may lie in technology rather than in approaches that place the burden on reporters to provide precise information. For example, intelligent reporting interfaces could extract product details from images or guide users to provide the most relevant data, while integration with systems like electronic health records could facilitate data sharing. 24 , 25 , 26 , 27 By investing in these technological pathways, the pharmacovigilance field can move toward capturing accurate product‐level data more systematically, enhancing safety surveillance for all medicines. LIMITATIONS Several limitations warrant consideration when interpreting these findings. We recognize the potential for misclassification of biosimilar reports and assessed this in two ways. Our text‐string search approach may have underestimated suffix utilization due to misspellings or formatting variations in unstructured fields; however, manual review of all verbatim suspect product entries reported with a frequency greater than five identified no misspellings of biosimilar suffixes. We also assessed for misclassification of reports mentioning a suffix but erroneously coded to the reference product by searching for suffix mentions in reports coded to the five reference products with the highest biosimilar report volumes. We identified negligible misclassification rates (confirmed rates between 0.01% and 0.08%). Based on this very low incidence, we did not evaluate all biosimilar suffix mentions across all reference products reports. As our misclassification assessment focused specifically on suffix mentions rather than broader misclassification issues identifiable via product name or manufacturer mentions in narratives, the misclassification findings should not be interpreted as representative of misclassification rates of biosimilar reports in general. Additionally, AEMS data are subject to well‐documented limitations inherent to spontaneous AE reporting systems, including underreporting, variable report quality, and inconsistent documentation practices across different reporter types and settings. 14 The voluntary nature of most submissions means our findings may not fully represent all AEs occurring with biosimilar products. Therefore, these data reflect reporting behaviors but not the reasons for them; consequently, we cannot determine why reporters included or excluded suffixes. FUNDING No funding was received for this work. CONFLICT OF INTEREST The authors declared no competing interests for this work. AUTHOR CONTRIBUTIONS D.S., L.W., M.S.R., and M.A.M. wrote the manuscript; D.S., L.W., M.S.R., and M.A.M. designed the research; D.S., L.W., M.S.R., and M.A.M. performed the research; D.S., L.W., and M.A.M. analyzed the data. DISCLAIMER The opinions expressed in this manuscript are those of the authors and not necessarily those of the US Food and Drug Administration or the US Government. Supporting information Table S1. Table S2.